Reviews in Endocrine & Metabolic Disorders最新文献

{"title":"Looking beyond fat in obesity: the frequently overlooked importance of muscle mass.","authors":"Refaat Hegazi, Bruno Halpern","doi":"10.1007/s11154-025-09986-1","DOIUrl":"https://doi.org/10.1007/s11154-025-09986-1","url":null,"abstract":"<p><p>Obesity is traditionally defined as \"abnormal or excessive fat accumulation that presents a health risk,\" yet this definition lacks precision and fails to account for individual variability in body composition. The continued reliance on body mass index (BMI) as a diagnostic tool further complicates accurate assessment, as BMI does not differentiate between fat mass and lean mass. Emerging evidence highlights that health risks associated with obesity are not solely determined by fat accumulation, but also by the relative deficiency in fat-free mass, particularly muscle. Despite this, the role of muscle health in obesity management remains underappreciated in clinical practice. With the advent of potent pharmacotherapies for obesity, such as a new class of GLP-1 receptor agonists, there is growing concern about their impact on muscle mass during weight loss. This underscores the need for a more holistic understanding of body composition changes and their implications for long-term health. This special issue of Reviews in Endocrine and Metabolic Disorders addresses these critical gaps, offering diverse perspectives on integrating muscle health into the continuum of obesity care.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in gestational diabetes prevalence in China from 1990 to 2024: a systematic review and meta-analysis.","authors":"Xiaodong Wu, Henning Tiemeier, Tingting Xu","doi":"10.1007/s11154-025-09987-0","DOIUrl":"https://doi.org/10.1007/s11154-025-09987-0","url":null,"abstract":"<p><p>This study examines the 34-year trends in gestational diabetes mellitus (GDM) prevalence in China, analyzing diagnostic shifts, regional variations, and urban-rural disparities. A comprehensive search of PubMed, Scopus, EMBASE, Google Scholar, WanFang, and China National Knowledge Infrastructure was conducted, ultimately including 1,105 articles after screening and data extraction. The study used multilevel meta-analysis to calculate pooled GDM prevalence and meta-regression to estimate trends and identify sources of heterogeneity. The results show that GDM prevalence based on the International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria was 2 to 3 times higher (15.6%, [95% CI 14.9-16.2%]) in pregnant women post-2010, compared to other criteria (e.g., World Health Organization: 7.1%, [95%CI 4.1-10.0%]). A consistent upward trend in GDM prevalence was observed across all criteria except for ADA/C&C samples. Notably, the urban-rural gap in GDM prevalence is narrowing, with rural areas experiencing a faster increase in GDM rates (rural: 0.90% per year, urban: 0.60% per year). Additionally, regional differences are becoming less pronounced. The study highlights the significant and rapid rise in GDM prevalence in China over the past 34 years, with a notable shift in regional patterns. The narrowing of the urban-rural disparity and the diminishing regional differences underscore the need for unified national guidelines and targeted healthcare strategies to address the growing prevalence of GDM across diverse populations.Protocol registration.Systematic review registration PROSPERO CRD42019135521.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine and metabolic consequences of childhood-onset craniopharyngioma during the transition age: A literature review by the TALENT study group.","authors":"Dario De Alcubierre, Tiziana Feola, Giulia Puliani, Rosario Ferrigno, Maria Elisa Amodeo, Francesco d'Aniello, Rosa Pirchio, Valentina Sada, Carla Pandozzi, Franz Sesti, Daniele Gianfrilli, Andrea M Isidori, Ashley B Grossman, Emilia Sbardella","doi":"10.1007/s11154-025-09972-7","DOIUrl":"https://doi.org/10.1007/s11154-025-09972-7","url":null,"abstract":"<p><p>Craniopharyngiomas are frequently diagnosed during childhood and adolescence, crucial periods for physical and psychosocial development. Despite improvements in survival rates, patients with childhood-onset craniopharyngioma face a wide array of lifelong complications, which emerge or worsen during adolescence, complicating the transition to adult care. Nevertheless, the transition age (15-25 years) remains an understudied phase in clinical practice. This narrative review synthesises current literature on the endocrine, neurocognitive, and metabolic consequences of transition-age childhood-onset craniopharyngiomas, providing a practical clinical approach to their diagnosis and management, along with an overview of emerging treatment strategies. Childhood-onset craniopharyngiomas are frequently associated with pituitary hormone deficiencies, which typically worsen post-treatment. While replacement protocols largely mirror those for adult patients, particular emphasis should be placed on patient education and optimal timing of treatment, especially regarding puberty induction and growth hormone replacement. Emerging therapies, such as long-acting growth hormone and modified-release hydrocortisone, should be considered to improve compliance. Hypothalamic dysfunction, both pre- and post-treatment, can lead to obesity, sleep disorders, and cognitive impairment. GLP-1 receptor agonists and melanocortin receptor agonists have recently shown promise in managing hypothalamic obesity. Sleep disturbances and cognitive impairment, often overlooked in clinical practice, should be systematically assessed in patients with hypothalamic involvement. Cardiovascular and bone health complications should be proactively addressed to improve long-term outcomes. Childhood-onset craniopharyngioma survivors require multidisciplinary care, particularly during the transition to adulthood. Timely endocrine management, individualised treatment strategies, and emerging targeted therapies are crucial for optimising quality of life and metabolic and neurocognitive outcomes.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144576199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging evidence and potential avenues to achieve durable outcomes in patients with obesity: the confluence of nutrition, and Microbiome on body composition.","authors":"Dra M Isabel T D Correia, Nitin Kapoor, Emma Chávez-Manzanera, Luís Henrique Wolff Gowdak, Amira Al Kharusi, Felipe F Casanueva, Bruno Halpern, Gary Frost, Raed Aldahash","doi":"10.1007/s11154-025-09977-2","DOIUrl":"https://doi.org/10.1007/s11154-025-09977-2","url":null,"abstract":"<p><p>Obesity is a global health concern that impacts health, quality of life, and longevity in affected individuals. Comorbid cardiovascular disease, type 2 diabetes, cancer, and other conditions often accompany obesity, and researchers are actively investigating therapeutic strategies to treat obesity and mitigate the health risks associated with excess adiposity. Restrictive nutritional intake and body weight reduction through lifestyle behavioral interventions, bariatric procedures, and highly effective anti-obesity medications are all recommended treatments for obesity. Meanwhile, the caloric restriction that comes with very low-calorie diets can result in changes in body composition, most notably a progressive loss of muscle mass and/or functionality, a process that can be accelerated by aging, underlying metabolic disease, or inadequate protein intake seen with many dietary patterns. While muscle loss was previously understood as a condition only affecting older individuals, this outcome is common in patients with obesity. The term sarcopenic obesity has been used to refer to this condition, and it is now recognized as an important potential complication in all patients with obesity. Dietary challenges that influence overall body composition also have drawn attention to the gut microbiome, a topic of growing interest as there is an increasingly recognized interplay between diet, the metabolic actions of microorganisms in the gut that impact macronutrient and micronutrient production and absorption, and human health. This article will review the current understanding of obesity as a chronic disease, the impact of diet and nutritional therapy on body composition, and the potential relevance of the gut microbiome in this setting.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144542026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body mass index and body composition changes in transgender people undergoing gender-affirming hormone therapy: a systematic review and meta-analysis.","authors":"Ísis Gois, Felipe Behrends Rodrigues, Marcos Pereira, Magnus R Dias-da-Silva, Sávio Marcelino Gomes","doi":"10.1007/s11154-025-09985-2","DOIUrl":"https://doi.org/10.1007/s11154-025-09985-2","url":null,"abstract":"<p><p>Gender-affirming hormone therapy (GAHT) uses sex steroid hormones to induce desired physical changes, improving the quality of life of transgender individuals. While generally considered safe, its effects on body composition and adipose tissue remain a topic of debate. The aim of this review was to verify whether GAHT is associated with weight gain and body composition in transgender individuals. This is a systematic review with meta-analysis (April-September 2022, updated March 2025) following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including cohort, case‒control, and clinical trial studies from four databases. The outcomes analyzed included body mass index (BMI), body fat (BF), lean mass (LM), and waist circumference (WC). Among the 1,896 identified studies, 29 were included in the systematic review, and 28 were included in the meta-analysis. GAHT increased BMI in assigned male at birth (AMAB) individuals (0.55 kg/m², 95% CI: 0.14-0.97) and assigned female at birth (AFAB) individuals (0.92 kg/m², 95% CI: 0.55-1.29). The AMAB participants presented a reduction in LM (-1.81 kg, 95% CI: -3.15, -0.47) and an increase in BF (4.27 kg, 95% CI: 3.15-5.39), whereas the AFAB individuals presented an increase in LM (4.98 kg, 95% CI: 4.06-5.91) and a decrease in BF (-2.13 kg, 95% CI: -3.52, -0.75). No significant changes in WC were observed in either group. According to the GRADE assessment, the certainty of evidence was moderate for BMI and low to very low for changes in waist circumference, lean mass, and fat mass. GAHT is associated with increased BMI and body composition changes. These alterations align with the expected outcomes for transgender individuals and do not appear to be directly linked to cardiovascular risks.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperphagia in rare melanocortin-4 receptor pathway diseases: therapeutic options and assessing treatment response.","authors":"Jesús Argente, Karine Clément, Jessica Duis, I Sadaf Farooqi, Peter Kühnen, Jennifer L Miller, Christian L Roth, Erica van den Akker","doi":"10.1007/s11154-025-09984-3","DOIUrl":"https://doi.org/10.1007/s11154-025-09984-3","url":null,"abstract":"<p><p>Hyperphagia is a hallmark of both congenital and acquired rare melanocortin-4 receptor (MC4R) pathway diseases. Currently, the medical community has no standard treatment guidelines or approach to establishing treatment benefit. This narrative review discusses current understandings of the pathophysiology, burden, and treatment of hyperphagia and summarizes findings from a systematic literature review of validated instruments for assessing the response to hyperphagia treatment. Hyperphagia can result from dysfunction within, or damage impacting, hypothalamic pathways including the MC4R pathway, a key regulator of energy balance. The burden of hyperphagia is substantial, with negative effects experienced across physiologic, emotional, and social domains. Approaches for hyperphagia management include environmental control, lifestyle intervention, pharmacotherapy, neurocognitive approaches, and neurostimulation. There are varied approaches to determine treatment response; however, standard methodology has not been determined and largely relies on questionnaires. Studies of rare MC4R pathway diseases have improved understanding of the etiology of hyperphagia and established the need for indication-specific treatment. Targeted treatments are limited, and methods for determining treatment efficacy are varied. There is a need for consensus guidelines to establish a standard approach for the management of hyperphagia and related assessment of treatment response to improve patient morbidity.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis.","authors":"Thendo I Mabuda, Nicole R S Sibuyi, Adewale O Fadaka, Mervin Meyer, Abram M Madiehe, Kwazikwakhe B Gabuza","doi":"10.1007/s11154-025-09980-7","DOIUrl":"https://doi.org/10.1007/s11154-025-09980-7","url":null,"abstract":"","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BBSome: An essential component of hypothalamic regulation of energy homeostasis.","authors":"Deng Fu Guo, Yuying Zhao, Connor Laule, Kamal Rahmouni","doi":"10.1007/s11154-025-09979-0","DOIUrl":"https://doi.org/10.1007/s11154-025-09979-0","url":null,"abstract":"<p><p>The BBSome is a protein complex composed of eight Bardet-Biedl syndrome (BBS) proteins. Although the BBSome is best known for its role in regulating cilia function, accumulating evidence indicates that this protein complex is also involved in various cellular processes, including mitochondrial dynamics and receptor trafficking to the plasma membrane. BBSome deficiency is associated with a range of diseases, including obesity and type 2 diabetes. Research into the mechanisms underlying metabolic disorders caused by BBSome deficiency has uncovered novel pathways of metabolic regulation, particularly within the hypothalamus. In this review, we discuss recent advances in understanding the role of the hypothalamic BBSome in the control of energy and glucose homeostasis and explore the underlying mechanisms.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual dimorphism in the development and function of the melanocortin system.","authors":"Marc Claret, Roberta Haddad-Tóvolli","doi":"10.1007/s11154-025-09983-4","DOIUrl":"https://doi.org/10.1007/s11154-025-09983-4","url":null,"abstract":"<p><p>The melanocortin system is fundamental for the regulation of whole-body energy homeostasis. This system consists of pro-opiomelanocortin (POMC) and agouti-related peptide (AgRP) neurons in the arcuate nucleus of the hypothalamus (ARH), as well as downstream neurons expressing melanocortin receptors (MCRs) located in various brain regions. Emerging evidence highlights significant anatomical and functional sex differences within the melanocortin system, influencing sex-dimorphic metabolic adaptations, the regulation of appetite and energy expenditure and susceptibility to metabolic conditions. These differences are primarily shaped by sex hormones, genetic and environmental factors as well as distinct neurocircuitry organization between males and females. These sex-specific regulatory mechanisms have important implications for the pathophysiology of metabolic disorders, including obesity, type 2 diabetes, and eating disorders. In this review, we explore current knowledge on sex differences in the development and function of the melanocortin system and how this is translated into sex-dimorphic control of metabolism. This emphasizes the need to incorporate sex as a critical variable in both metabolic research and clinical studies. Understanding these mechanisms may provide more precise and effective therapeutic strategies for metabolic disorders, obesity, and appetite dysregulation in both sexes.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between continuous glucose monitoring metrics and cardiovascular autonomic neuropathy in diabetic patients: a systematic review.","authors":"Yifan Jia, Dan Long, Wei Song, Qiong Wang, Qian Zhang","doi":"10.1007/s11154-025-09981-6","DOIUrl":"10.1007/s11154-025-09981-6","url":null,"abstract":"<p><p>Cardiovascular autonomic neuropathy (CAN) is a serious and prevalent complication of diabetes, linked to significant morbidity and mortality. Continuous glucose monitoring systems (CGM) provide a comprehensive and continuous glucose profile, enabling precise assessment of glycemic variability, hypoglycemia, and other key glucose metrics. Despite the increasing use of CGM, the relationship between CGM-derived metrics and CAN risk has yet to be rigorously evaluated. A systematic search of PubMed, Cochrane Library, Web of Science, Medline, and Embase was conducted up to 30 September 2024. Eligible observational studies assessed the association between CGM metrics and CAN in diabetic adults, using ORs with 95% CIs. Heterogeneity was evaluated via Cochrane's Q and I² statistics, and meta-analysis was performed when at least three studies provided comparable CGM metrics and outcomes. Sixteen studies involving 1,814 participants were included in the systematic review. Among these, four studies each for coefficients of variation (CV) and standard deviation (SD), and five studies for mean amplitude of glycemic excursions (MAGE) provided data suitable for meta-analysis. Higher CV (OR 1.08; 95% CI 1.04-1.12) and SD (OR 1.03; 95% CI 1.01-1.06) were significantly associated with increased CAN risk, whereas MAGE was not significantly associated (OR 1.01; 95% CI 0.99-1.03). Other metrics such as time in range (TIR), time above/below range (TAR/TBR), and low blood glucose index (LBGI) showed inconsistent results across studies and were synthesized narratively. Higher glycemic variability, notably CV and SD, is linked to increased CAN risk in patients with diabetes. Monitoring CGM metrics may aid early detection and management of CAN. Further high-quality longitudinal studies are warranted.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":" ","pages":""},"PeriodicalIF":6.9,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}